On Google.com search for below:

"entourage biotech" "Nerium SkinCare"

You will get one result. Click on that; it is a FDA Excel file = Open that Excel file, scroll down to line 9787.

The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW’s Chief Executive Officer. "This journey began with requests from the U.S. epilepsy physician and patient community to utilize Epidiolex and has now led to GW embarking on its own formal development program with a view to seeking market authorization from the FDA as rapidly as possible. We are committed to providing a prescription cannabidiol (CBD) medicine for children with Dravet syndrome who have exhausted all other therapeutic options.

In Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
“By employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development,” said Omni Health’s CEO, Andrey Soloviev.

I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

MIAMI, FL / ACCESSWIRE / September 27, 2018 / Omni Health, Inc. (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceuticals, anti-aging products, and biotech engineering, today announced that it finalizes agreements to acquire 2 privately held companies in the coveted medical technology field and plans to announce the details in the coming weeks.

We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.

The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW’s Chief Executive Officer. "This journey began with requests from the U.S. epilepsy physician and patient community to utilize Epidiolex and has now led to GW embarking on its own formal development program with a view to seeking market authorization from the FDA as rapidly as possible. We are committed to providing a prescription cannabidiol (CBD) medicine for children with Dravet syndrome who have exhausted all other therapeutic options.

In Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
“By employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development,” said Omni Health’s CEO, Andrey Soloviev.

MIAMI, FL--(Marketwired - Feb 9, 2017) - Omni Health, Inc. ( OTC PINK : OMHE ) has released a letter from President & CEO Andrey Soloviev to update shareholders on the current status of the Company.

Dear Fellow Shareholders,

This letter is the first of many in which I will be communicating with you directly on a regular basis so that you may have total visibility into the business.

Today, February 9th, 2017, is the 43rd anniversary of the founding of Malecon Pharmacy, a division of Omni Health. As Chief Executive Officer, I'm proud to lead an organization that has achieved a great deal throughout its history.

Reflecting on my 10 years with this company, I feel I've been blessed to work with an exceptionally talented group of employees. Together, with our management team, our employees have built one of the most respected health care providers in the region. The hard work and dedication of these men and women have allowed us to earn the trust of the patients and the communities we serve. Their efforts have made it possible for us to continue more than four decades of growth. Our revenues have grown to more than $6 million a year, and each year, our company has been getting stronger and more secure.

We've accomplished a lot and this fills me with tremendous pride, but Omni Health is only just beginning to realize its full potential. Our mission to improve the health and wellness of our communities is what drives us as an organization to innovate; to improve the delivery of services and products that are essential to the wellbeing of tens of thousands of customers.

We will continue to innovate and continue to build on what we've accomplished. To do so, our vision is to capitalize on decades of knowledge and experience to create a global health and wellness company. To that end, we plan to rapidly expand our operations to include new divisions in the areas of specialty pharmaceuticals, anti-aging brands, and therapeutic cannabis products and licensed medical marijuana cultivation. Currently, we are in the final states of several strategic acquisitions to accelerate our bold expansion. Our pipeline of new products and breakthrough innovation has never been more robust.

To successfully implement our plans, Omni Health has been accumulating clinical research, regulatory experience and technology. We've recruited professional talent and we are building critical infrastructure.

The core values that Omni Health upholds have helped enable success over the long term. Number one is our commitment to ensure that the day-to-day costs of running the company do not impede our ability to invest for tomorrow, and deliver strong and improving profitability today. As we have transitioned from a privately held enterprise into a public company, we have incurred some significant costs along the way. Once this transition is behind us, we will be better able to contain operating costs, have more resources available for strategic acquisitions, and see profits increase to strengthen our capital base and support business growth.

Another core value recognizes the importance of diversification while carrying out our mission. We envision our growth to be based on a very solid foundation. What Omni Health is building is essentially an ecosystem in which each of the new divisions I've mentioned above will funnel relationships in each other and create mutually beneficial synergies.

As the CEO of Omni Health, I couldn't ask for a better foundation to build upon. It's an honor for me to serve and to lead this great company of ours as we reach for new heights.

In the coming months, I will be delighted to announce the formation of the international board of directors. We intend to bring in some of the most respected names in our field. This board will work closely with the leadership team to shape and guide Omni Health's strategy going forward.

As I've communicated to you previously, we will soon be upgrading to the OTCQB market.

We will soon be unveiling a new company web portal that will serve as the go-to resource for up-to-date information about developments at Omni Health. Look for more exciting news to come.

As always, my gratitude extends to you -- our valued stockholders -- for your continued support for our shared business objectives.



Sincerely,
Andrey Soloviev CEO

Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.

Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles. Given the potency of these analgesics, they will be marketed and distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate patient support and product usage. As per the current schedule, it’s anticipated they this product will be introduced to the North American market during Q3 2018. Based on current market trends and competitor analysis, Omni Health projects generating a recurring annual revenue exceeding $7 Million.

“The Global Market for Pain Management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022 and the Cannabidiol (CBD) market is estimated to grow by 700% by 2020”, concluded Andrey Soloviev, “As such, there is a unique potential for Omni Health to truly seize the day by bringing the first FDA registered CBD pain analgesic to the market”

To successfully implement our plans, Omni Health has been accumulating clinical research, regulatory experience and technology. We've recruited professional talent and we are building critical infrastructure.

MIAMI, FL--(Marketwired - May 4, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced today the grand opening of its state of the art biotech R&D and manufacturing laboratory facility in Miami, Florida.

Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.

In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

MIAMI, FL / ACCESSWIRE / September 27, 2018 / Omni Health, Inc. (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceuticals, anti-aging products, and biotech engineering, today announced that it finalizes agreements to acquire 2 privately held companies in the coveted medical technology field and plans to announce the details in the coming weeks.

MIAMI, FL / ACCESSWIRE / September 27, 2018 / Omni Health, Inc. (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceuticals, anti-aging products, and biotech engineering, today announced that it finalizes agreements to acquire 2 privately held companies in the coveted medical technology field and plans to announce the details in the coming weeks.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

To successfully implement our plans, Omni Health has been accumulating clinical research, regulatory experience and technology. We've recruited professional talent and we are building critical infrastructure.

MIAMI, FL--(Marketwired - May 4, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced today the grand opening of its state of the art biotech R&D and manufacturing laboratory facility in Miami, Florida.

Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.

In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.

The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.

We will continue to innovate and continue to build on what we've accomplished. To do so, our vision is to capitalize on decades of knowledge and experience to create a global health and wellness company. To that end, we plan to rapidly expand our operations to include new divisions in the areas of (1) specialty pharmaceuticals, (2) anti-aging brands, and (3) therapeutic cannabis products and (4) licensed medical marijuana cultivation. Currently, we are in the final states of several strategic acquisitions to accelerate our bold expansion. Our pipeline of new products and breakthrough innovation has never been more robust.